{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T04:51:21Z","timestamp":1794199881659,"version":"4.8.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T00:00:00Z","timestamp":1682726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T00:00:00Z","timestamp":1682726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objective<\/jats:title>\n                    <jats:p>The efficacy and safety of L-carnitine supplementation on non-alcoholic fatty liver disease (NAFLD) are unclear. This systematic review and meta-analysis aimed to assess the efficacy and safety of L-carnitine supplementation on NAFLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched in four databases (PubMed, Embase, Cochrane Library, and Web of Science) from inception to 1 November 2022 (updated on March 20, 2023) for potentially relevant records without language restrictions. We collected information on the first author, publication year, country, setting, study design, population characteristics, duration of follow-up, outcome variables of interest, and sources of funding. We used a modified Cochrane risk of bias tool to assess the risk of bias, used GRADE to assess the certainty of evidence, and used the Credibility of Effect Modification Analyses (ICEMAN) tool to assess the credibility of any apparent subgroup effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This systematic review and meta-analysis included eight eligible randomized controlled trials (RCTs). Compared to placebo,\u00a0low certainty evidence show that L-carnitine supplementation significantly changes (reduced) more\u00a0in AST levels and ALT levels (MD:\u2009\u2212\u200926.38, 95%CI:\u2009\u2212\u200945.46 to\u2009\u2212\u20097.30),\u00a0and\u00a0moderate certainty evidence show that L-carnitine supplementation significantly changes (reduced)\u00a0more\u00a0in HDL cholesterol levels (MD: 1.14, 95%CI: 0.21 to 2.07) and triglyceride levels (MD:\u2009\u2212\u20096.92, 95%CI:\u2009\u2212\u200913.82 to\u2009\u2212\u20090.03). Moderate credibility of ICEMAN results shows that L-carnitine supplementation has no difference in changes of AST and ALT levels in younger ones (MD: 0.5, 95%CI:\u2009\u2212\u20090.70 to 1.70) but has significant changes (reduced) in adults (MD:\u2009\u2212\u200920.3, 95%CI:\u2009\u2212\u200928.62 to\u2009\u2212\u200912.28)\u00a0compared to placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>L-carnitine supplementation may improve liver function and regulate triglyceride metabolism in patients with NAFLD, and with no significant adverse effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13643-023-02238-w","type":"journal-article","created":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T03:02:16Z","timestamp":1682737336000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy and safety of carnitine supplementation on NAFLD: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"12","author":[{"given":"Aiping","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongquan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingzu","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,29]]},"reference":[{"key":"2238_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12916-017-0806-8","volume":"15","author":"BA Neuschwander-Tetri","year":"2017","unstructured":"Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med. 2017;15:45.","journal-title":"BMC Med"},{"key":"2238_CR2","doi-asserted-by":"crossref","unstructured":"Wiering L, Tacke F: Treating inflammation to combat non-alcoholic fatty liver disease. J Endocrinol 2023;256.","DOI":"10.1530\/JOE-22-0194"},{"key":"2238_CR3","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41575-019-0169-z","volume":"16","author":"V Nobili","year":"2019","unstructured":"Nobili V, Alisi A, Valenti L, Miele L, Feldstein AE, Alkhouri N. NAFLD in children: new genes, new diagnostic modalities and new drugs. Nat Rev Gastroenterol Hepatol. 2019;16:517\u201330.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2238_CR4","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/joim.12719","volume":"283","author":"P Dongiovanni","year":"2018","unstructured":"Dongiovanni P, Stender S, Pietrelli A, Mancina RM, Cespiati A, Petta S, Pelusi S, Pingitore P, Badiali S, Maggioni M, et al. Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. J Intern Med. 2018;283:356\u201370.","journal-title":"J Intern Med"},{"key":"2238_CR5","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397:2212\u201324.","journal-title":"Lancet"},{"key":"2238_CR6","doi-asserted-by":"publisher","first-page":"6549","DOI":"10.3748\/wjg.v23.i36.6549","volume":"23","author":"S Singh","year":"2017","unstructured":"Singh S, Osna NA, Kharbanda KK. Treatment options for alcoholic and non-alcoholic fatty liver disease: a review. World J Gastroenterol. 2017;23:6549\u201370.","journal-title":"World J Gastroenterol"},{"key":"2238_CR7","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","volume":"70","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM. Non-alcoholic fatty liver disease - a global public health perspective. J Hepatol. 2019;70:531\u201344.","journal-title":"J Hepatol"},{"key":"2238_CR8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2337\/diacare.27.1.155","volume":"27","author":"JS Torgerson","year":"2004","unstructured":"Torgerson JS, Hauptman J, Boldrin MN, Sj\u00f6str\u00f6m L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155\u201361.","journal-title":"Diabetes Care"},{"key":"2238_CR9","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2174\/138920011796504536","volume":"12","author":"J Pekala","year":"2011","unstructured":"Pekala J, Patkowska-Soko\u0142a B, Bodkowski R, Jamroz D, Nowakowski P, Lochy\u0144ski S, Librowski T. l-carnitine\u2013metabolic functions and meaning in humans life. Curr Drug Metab. 2011;12:667\u201378.","journal-title":"Curr Drug Metab"},{"key":"2238_CR10","first-page":"Cd013601","volume":"12","author":"N Nishioka","year":"2022","unstructured":"Nishioka N, Luo Y, Taniguchi T, Ohnishi T, Kimachi M, Ng RC, Watanabe N. Carnitine supplements for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev. 2022;12:Cd013601.","journal-title":"Cochrane Database Syst Rev."},{"key":"2238_CR11","doi-asserted-by":"crossref","unstructured":"Savic D, Hodson L, Neubauer S, Pavlides M. The importance of the fatty acid transporter l-carnitine in non-alcoholic fatty liver disease (NAFLD). Nutrients. 2020;12(8):2178.","DOI":"10.3390\/nu12082178"},{"key":"2238_CR12","doi-asserted-by":"publisher","first-page":"689042","DOI":"10.3389\/fmed.2021.689042","volume":"8","author":"N Li","year":"2021","unstructured":"Li N, Zhao H. Role of carnitine in non-alcoholic fatty liver disease and other related diseases: an update. Front Med (Lausanne). 2021;8:689042.","journal-title":"Front Med (Lausanne)"},{"key":"2238_CR13","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.17554\/j.issn.2224-3992.2016.05.662","volume":"5","author":"P Alavinejad","year":"2016","unstructured":"Alavinejad P, Zakerkish M, Hajiani E, Hashemi SJ, Chobineh M, Moghaddam EK. Evaluation of l-carnitine efficacy in the treatment of non-alcoholic fatty liver disease among diabetic patients: a randomized double blind pilot study. J Gastroenterol Hepatol Res. 2016;5:2191\u20135.","journal-title":"J Gastroenterol Hepatol Res"},{"key":"2238_CR14","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/jebm.12443","volume":"14","author":"J Tian","year":"2021","unstructured":"Tian J, Gao Y, Zhang J, Yang Z, Dong S, Zhang T, Sun F, Wu S, Wu J, Wang J, et al. Progress and challenges of network meta-analysis. J Evid Based Med. 2021;14:218\u201331.","journal-title":"J Evid Based Med"},{"key":"2238_CR15","doi-asserted-by":"publisher","first-page":"102273","DOI":"10.1016\/j.ctim.2019.102273","volume":"48","author":"M Abolfathi","year":"2020","unstructured":"Abolfathi M, Mohd-Yusof BN, Hanipah ZN, MohdRedzwan S, Yusof LM, Khosroshahi MZ. The effects of carnitine supplementation on clinical characteristics of patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. Complement Ther Med. 2020;48:102273.","journal-title":"Complement Ther Med"},{"key":"2238_CR16","first-page":"135","volume":"13","author":"S Amiri-Moghadam","year":"2015","unstructured":"Amiri-Moghadam S, Nematy M, Eghtesadi S, Khalili M, Mojarrad M, Jazayeri S, Vosooghinia H, Khosravi A, Salehi M. Effects of l-carnitine supplementation on inflammatory factors and malondialdehyde in patients with nonalcoholic steatohepatitis (NASH). Curr Topics Nutraceutical Res. 2015;13:135\u201341.","journal-title":"Curr Topics Nutraceutical Res"},{"key":"2238_CR17","first-page":"71","volume":"13","author":"S Amiri-Moghadam","year":"2015","unstructured":"Amiri-Moghadam S, Nematy M, Eghtesadi S, Khalili M, Mojarrad M, Jazayeri S, Vosooghinia H, Khosravi A, Salehi M, Beheshti-Namdar A. Effects of l-carnitine supplementation on body composition in patients with nonalcoholic steatohepatitis (NASH). Curr Topics Nutraceutical Res. 2015;13:71\u20136.","journal-title":"Curr Topics Nutraceutical Res"},{"key":"2238_CR18","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1515\/jpem-2020-0642","volume":"34","author":"H Saneian","year":"2021","unstructured":"Saneian H, Khalilian L, Heidari-Beni M, Khademian M, Famouri F, Nasri P, Hassanzadeh A, Kelishadi R. Effect of l-carnitine supplementation on children and adolescents with nonalcoholic fatty liver disease (NAFLD): a randomized, triple-blind, placebo-controlled clinical trial. J Pediatr Endocrinol Metab. 2021;34:897\u2013904.","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2238_CR19","doi-asserted-by":"publisher","first-page":"e588","DOI":"10.1093\/pubmed\/fdac036","volume":"44","author":"MS Cumpston","year":"2022","unstructured":"Cumpston MS, McKenzie JE, Welch VA, Brennan SE. Strengthening systematic reviews in public health: guidance in the Cochrane Handbook for Systematic Reviews of Interventions, 2nd edition. J Public Health (Oxf). 2022;44:e588\u201392.","journal-title":"J Public Health (Oxf)"},{"key":"2238_CR20","doi-asserted-by":"publisher","first-page":"4221","DOI":"10.1016\/j.jaip.2021.09.035","volume":"9","author":"DK Chu","year":"2021","unstructured":"Chu DK, Golden DBK, Guyatt GH. Translating evidence to optimize patient care using GRADE. J Allergy Clin Immunol Pract. 2021;9:4221\u201330.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2238_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.","journal-title":"BMJ"},{"key":"2238_CR22","volume-title":"Modification of cochrane tool to assess risk of bias in randomized trials","author":"GH Guyatt","year":"2022","unstructured":"Guyatt GH, Busse JW. Modification of cochrane tool to assess risk of bias in randomized trials. 2022."},{"key":"2238_CR23","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1002\/sim.2380","volume":"25","author":"RM Harbord","year":"2006","unstructured":"Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med. 2006;25:3443\u201357.","journal-title":"Stat Med"},{"key":"2238_CR24","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"2238_CR25","doi-asserted-by":"publisher","first-page":"E901","DOI":"10.1503\/cmaj.200077","volume":"192","author":"S Schandelmaier","year":"2020","unstructured":"Schandelmaier S, Briel M, Varadhan R, Schmid CH, Devasenapathy N, Hayward RA, Gagnier J, Borenstein M, van der Heijden G, Dahabreh IJ, et al. Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. CMAJ. 2020;192:E901-e906.","journal-title":"CMAJ"},{"key":"2238_CR26","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, Montori V, Akl EA, Djulbegovic B, Falck-Ytter Y, et al. GRADE guidelines: 4. Rating the quality of evidence\u2013study limitations (risk of bias). J Clin Epidemiol. 2011;64:407\u201315.","journal-title":"J Clin Epidemiol"},{"key":"2238_CR27","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.zefq.2012.10.018","volume":"106","author":"M Perleth","year":"2012","unstructured":"Perleth M, Langer G, Meerpohl JJ, Gartlehner G, Kaminski-Hartenthaler A, Sch\u00fcnemann HJ. GRADE guidelines: 7. Rating the quality of evidence - inconsistency. Z Evid Fortbild Qual Gesundhwes. 2012;106:733\u201344.","journal-title":"Z Evid Fortbild Qual Gesundhwes"},{"key":"2238_CR28","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, Devereaux PJ, Montori VM, Freyschuss B, Vist G, et al. GRADE guidelines 6. Rating the quality of evidence\u2013imprecision. J Clin Epidemiol. 2011;64:1283\u201393.","journal-title":"J Clin Epidemiol"},{"key":"2238_CR29","unstructured":"Shao SC, Kuo LT, Huang YT, Lai PC, Chi CC: Using Grading of Recommendations Assessment, Development, and Evaluation (GRADE) to rate the certainty of evidence of study outcomes from systematic reviews: a quick tutorial. Dermatologica Sinica 2023, [Epub ahead of print]:[cited 2023 Mar 2021] Available from: https:\/\/www.dermsinica.org\/preprintarticle.asp?id=368303."},{"key":"2238_CR30","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.jclinepi.2011.04.014","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, Alonso-Coello P, Falck-Ytter Y, Jaeschke R, Vist G, et al. GRADE guidelines: 8. Rating the quality of evidence\u2013indirectness. J Clin Epidemiol. 2011;64:1303\u201310.","journal-title":"J Clin Epidemiol"},{"key":"2238_CR31","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.jclinepi.2011.01.011","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, Alonso-Coello P, Djulbegovic B, Atkins D, Falck-Ytter Y, et al. GRADE guidelines: 5. Rating the quality of evidence\u2013publication bias. J Clin Epidemiol. 2011;64:1277\u201382.","journal-title":"J Clin Epidemiol"},{"key":"2238_CR32","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.2337\/dc14-2852","volume":"38","author":"JC Bae","year":"2015","unstructured":"Bae JC, Lee WY, Yoon KH, Park JY, Son HS, Han KA, Lee KW, Woo JT, Ju YC, Lee WJ, et al. Improvement of nonalcoholic fatty liver disease with carnitine-orotate complex in type 2 diabetes (CORONA): a randomized controlled trial. Diabetes Care. 2015;38:1245\u201352.","journal-title":"Diabetes Care"},{"key":"2238_CR33","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1111\/jgh.12536","volume":"29","author":"ES Hong","year":"2014","unstructured":"Hong ES, Kim EK, Kang SM, Khang AR, Choi SH, Park KS, Jang HC, Lim S. Effect of carnitine-orotate complex on glucose metabolism and fatty liver: a double-blind, placebo-controlled study. J Gastroenterol Hepatol. 2014;29:1449\u201357.","journal-title":"J Gastroenterol Hepatol"},{"key":"2238_CR34","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1038\/ajg.2009.719","volume":"105","author":"M Malaguarnera","year":"2010","unstructured":"Malaguarnera M, Gargante MP, Russo C, Antic T, Vacante M, Malaguarnera M, Avitabile T, Li Volti G, Galvano F. l-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis\u2013a randomized and controlled clinical trial. Am J Gastroenterol. 2010;105:1338\u201345.","journal-title":"Am J Gastroenterol"},{"key":"2238_CR35","doi-asserted-by":"publisher","first-page":"575","DOI":"10.6026\/97320630010575","volume":"10","author":"MH Somi","year":"2014","unstructured":"Somi MH, Fatahi E, Panahi J, Havasian MR, Judaki A. Data from a randomized and controlled trial of Lcarnitine prescription for the treatment for non-alcoholic fatty liver disease. Bioinformation. 2014;10:575\u20139.","journal-title":"Bioinformation"},{"key":"2238_CR36","doi-asserted-by":"publisher","first-page":"179","DOI":"10.4166\/kjg.2020.158","volume":"77","author":"NY Heo","year":"2021","unstructured":"Heo NY, Park SH, Choi JH, Kim E, Kim TO, Park J, Lee J, Park YE, Oh EH, Hwang JS, Jeong SJ. Efficacy and safety of biphenyl dimethyl dicarboxylate and ursodeoxycholic acid combination in chronic hepatitis related to metabolic syndrome components. Korean J Gastroenterol. 2021;77:179\u201389.","journal-title":"Korean J Gastroenterol"},{"key":"2238_CR37","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/hep4.1162","volume":"2","author":"R Mukherjee","year":"2018","unstructured":"Mukherjee R, Moreno-Fernandez ME, Giles DA, Cappelletti M, Stankiewicz TE, Chan CC, Divanovic S. Nicotinamide adenine dinucleotide phosphate (reduced) oxidase 2 modulates inflammatory vigor during nonalcoholic fatty liver disease progression in mice. Hepatol Commun. 2018;2:546\u201360.","journal-title":"Hepatol Commun"},{"key":"2238_CR38","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1016\/j.jhep.2022.08.019","volume":"78","author":"JD Spence","year":"2023","unstructured":"Spence JD. B vitamins for NASH: use methylcobalamin, not cyanocobalamin. J Hepatol. 2023;78:e34\u20135.","journal-title":"J Hepatol"},{"key":"2238_CR39","doi-asserted-by":"publisher","first-page":"938","DOI":"10.3945\/ajcn.111.012047","volume":"94","author":"FB Stephens","year":"2011","unstructured":"Stephens FB, Marimuthu K, Cheng Y, Patel N, Constantin D, Simpson EJ, Greenhaff PL. Vegetarians have a reduced skeletal muscle carnitine transport capacity. Am J Clin Nutr. 2011;94:938\u201344.","journal-title":"Am J Clin Nutr"},{"key":"2238_CR40","doi-asserted-by":"publisher","first-page":"626319","DOI":"10.1155\/2014\/626319","volume":"2014","author":"AA El-Sheikh","year":"2014","unstructured":"El-Sheikh AA, Rifaai RA. Peroxisome proliferator activator receptor (PPAR)-\u03b3 ligand, but not PPAR-\u03b1, ameliorates cyclophosphamide-induced oxidative stress and inflammation in rat liver. PPAR Res. 2014;2014:626319.","journal-title":"PPAR Res"},{"key":"2238_CR41","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1016\/j.bbadis.2014.08.004","volume":"1842","author":"N Gruben","year":"2014","unstructured":"Gruben N, Shiri-Sverdlov R, Koonen DP, Hofker MH. Nonalcoholic fatty liver disease: a main driver of insulin resistance or a dangerous liaison? Biochim Biophys Acta. 2014;1842:2329\u201343.","journal-title":"Biochim Biophys Acta"},{"key":"2238_CR42","doi-asserted-by":"publisher","first-page":"108951","DOI":"10.1016\/j.diabres.2021.108951","volume":"178","author":"M Faris","year":"2021","unstructured":"Faris M, Jahrami H, Abdelrahim D, Bragazzi N, BaHammam A. The effects of Ramadan intermittent fasting on liver function in healthy adults: a systematic review, meta-analysis, and meta-regression. Diabetes Res Clin Pract. 2021;178:108951.","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-023-02238-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-023-02238-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-023-02238-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T03:04:55Z","timestamp":1682737495000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-023-02238-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,29]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2238"],"URL":"https:\/\/doi.org\/10.1186\/s13643-023-02238-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2465125\/v1","asserted-by":"object"}]},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,29]]},"assertion":[{"value":"10 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"74"}}